Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo’s Global Expectations Counter Slower U.S. OTC Growth

This article was originally published in The Pink Sheet Daily

Executive Summary

The private labeler hopes its international expansion will help mitigate the impact of the return of major branded OTCs from J&J and Novartis to the market.

You may also be interested in...



Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth

Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.

Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth

Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.

Hemp Regulation Flags Raised By States Wave Tougher Compliance Cloud Over Industry

Without FDA regulatory pathway for hemp’s lawful use in supplements and food, some states are imposing more-stringent regulations while others allow sales of intoxicating ingredients not considered controlled substances as hemp derivatives.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel